1. Introduction {#sec1-ijms-18-01514}
===============

Bladder cancer is one of the most common malignancies worldwide \[[@B1-ijms-18-01514]\]. It includes two major types: non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). NMIBC treatment is represented by chemo- and/or immune-therapy, and requires constant monitoring to prevent the recurrence and evolution to muscle-invasive disease. Bladder cancer represents a major concern due to its frequent relapses and poor clinical outcome once the tumors progress to muscle-invasive disease \[[@B2-ijms-18-01514]\]. Patients with MIBC have limited survival rates due to the aggressive nature of the tumor and its characteristic resistance to chemo- and radiotherapy \[[@B3-ijms-18-01514]\]. Furthermore, in patients with MIBC, the risk of developing lymph node metastases increases and chemotherapy becomes inefficient \[[@B4-ijms-18-01514]\]. Up to date, the prognosis and treatment for patients with bladder cancer are based on their clinical and pathological parameters. The main drawback of these methods is that, even in some cases when tumors present similar histology, they respond differently to the same treatment \[[@B5-ijms-18-01514],[@B6-ijms-18-01514]\]. Therefore, conventional methods and molecular biomarkers should be coupled in order to improve the clinical care of these patients, as well as their outcomes \[[@B7-ijms-18-01514]\].

The metabolic transformations that trigger the switch from a normal cell to malignant bladder cancer cells are diverse and include various classes of molecules that act synergistically in extensive networks that affect normal cell behavior. These changes include the glucose metabolism, Phosphatidylinositol-4,5-bisphosphate 3-kinase/Protein Kinase B/mTOR (PI3K/AKT/mTOR) pathway, glycogen metabolism, and lipid metabolism \[[@B8-ijms-18-01514]\]. The bio-molecular profile for bladder cancer patients is described as having alterations that affect the cellular cycle cyclin-dependent kinase Inhibitor 2A(CDKN2A)/CDK4/CCND1, PI3K/AKT/mTOR), but also survival and growth Receptor tyrosine kinases/RAS (RTK/RAS) pathways, with FGFR3 mutation incidence higher in NMIBC \[[@B9-ijms-18-01514]\]. All these modifications entail different receptors, transporters, enzymes, but also non-coding RNA molecules. All these players can represent targets for precision medicine therapies.

2. Non-Coding RNAs {#sec2-ijms-18-01514}
==================

About 90% of the human genome is transcribed, but only 2% of the total genome-sequence is represented by protein-coding genes, the rest being considered, until recently, 'transcriptional noise' \[[@B10-ijms-18-01514]\]. With the progress of high-throughput DNA sequencing and array-based technologies, studies revealed that the human transcriptome produces various classes of functional non-coding RNAs which act as regulators of gene expression and play important parts in human diseases \[[@B11-ijms-18-01514]\]. There are two major classes of non-coding RNAs: small non-coding RNA and long non-coding RNA (lncRNA). The mature forms of these non-coding RNAs are never translated into proteins, but they act as regulators of gene expression. The mechanism of action assumes the complementary binding of the RNA molecules to the single stranded mRNA, thus blocking the translation into proteins of certain genes, or leading to the degradation of the mRNA, a process that has the same outcome \[[@B12-ijms-18-01514]\]. Besides, long non-coding RNAs (lncRNAs) are known being also involved in the epigenetic and post- transcriptional regulation of various genes whose alterations lead to a malignant phenotype \[[@B13-ijms-18-01514]\].

2.1. Micro-RNAs {#sec2dot1-ijms-18-01514}
---------------

Micro-RNAs (miRNAs) are an example of a small non-coding RNA subclass that has been intensively studied in the past few years. With sizes of approximately 22 nucleotides, these miRNAs act as post-transcriptional regulators of gene expression \[[@B14-ijms-18-01514]\]. In addition, there is an increasing number of publications regarding the role of these non-coding RNAs as tumor suppressor genes or as oncogenes \[[@B15-ijms-18-01514],[@B16-ijms-18-01514]\]. Concerning their role in malignant cells, miRNAs are proficient in altering highly regulated mRNA networks \[[@B17-ijms-18-01514]\]. Abnormally expressed miRNAs in bladder cancer are of crucial importance, as they can represent valuable indications of the molecular mechanisms that underlie the development, progression, and metastasis in this type of malignancy. Besides, their small size and their ability to be extravasated from cells via exosomes prevent them from being digested by RNAses in the blood flow, enabling them to move freely within biological fluids (cell-free miRNAs) \[[@B18-ijms-18-01514],[@B19-ijms-18-01514]\]. Therefore, miRNAs represent a category of interest due to their potential significance as biomarkers for the diagnosis/prognosis of patients with bladder cancer, by means of using minimally invasive methods \[[@B20-ijms-18-01514]\].

There is an increasing number of studies concerning this issue which have reported downregulated \[[@B21-ijms-18-01514],[@B22-ijms-18-01514],[@B23-ijms-18-01514],[@B24-ijms-18-01514],[@B25-ijms-18-01514]\] or upregulated \[[@B22-ijms-18-01514],[@B26-ijms-18-01514],[@B27-ijms-18-01514]\] miRNAs in bladder cancer. These aberrantly expressed miRNAs in bladder cancer may reveal specific signatures, such as the miR-195/497 cluster, which acts as a tumor suppressor by modulating the expression of several genes, including *BIRC5* \[[@B21-ijms-18-01514]\]---a gene associated with inhibition of apoptosis \[[@B28-ijms-18-01514]\]. In bladder urothelial carcinoma, miR-182 and miR-183 were reported to be upregulated and miR-143 downregulated, when compared with normal urothelial tissue \[[@B22-ijms-18-01514]\], results that confirm the published work of other researchers \[[@B26-ijms-18-01514],[@B27-ijms-18-01514]\]. The downregulation of miR-8 family members in MIBC compared with NMIBC was previously reported \[[@B29-ijms-18-01514]\] and confirmed \[[@B24-ijms-18-01514]\]. The family members include miR-141, miR-200a, miR-200b, miR-200c, and miR-429, and they exert their function of inhibiting the epithelial-to-mesenchymal transition (EMT) by complementary binding to the Zinc finger E-box-binding homeobox 1/2 genes (*ZEB1/2*) \[[@B30-ijms-18-01514]\].

The crucial importance of these miRNAs in bladder cancer is revealed by the fact that they target critical genes connected to pathways that regulate proliferation \[[@B31-ijms-18-01514]\], invasiveness \[[@B32-ijms-18-01514],[@B33-ijms-18-01514],[@B34-ijms-18-01514],[@B35-ijms-18-01514]\], apoptosis \[[@B36-ijms-18-01514],[@B37-ijms-18-01514]\], resistance to therapy \[[@B38-ijms-18-01514]\], and other features that define the malignant transformation. These unnatural aspects arise from the disruption of different pathways, such as EMT, PI3K/AKT signaling, oxidative stress, Wnt signaling pathways etc. ([Figure 1](#ijms-18-01514-f001){ref-type="fig"}). It was previously reported that microRNAs are useful biomarkers for diagnostic and prognostic, for differentiating tumor tissue from normal tissue, and for stratification of patients with the same expression pattern \[[@B39-ijms-18-01514]\]. [Table 1](#ijms-18-01514-t001){ref-type="table"} presents the studies reporting the validated target genes of various miRNAs that were found to be dysregulated in bladder cancer patients and in various cell lines. The validation of the target genes for each miRNA in [Table 1](#ijms-18-01514-t001){ref-type="table"} was assessed on bladder cancer cell lines. As expected, the aberrantly expressed miRNAs have been observed to disturb metabolic pathways associated with malignant transformation.

2.2. Long Non-Coding RNAs {#sec2dot2-ijms-18-01514}
-------------------------

An important difference between lncRNAs and miRNAs lies in their size, with lncRNAs having more than 200 nucleotides. These types of non-coding RNAs share different characteristics with messenger RNAs, as they comprise several exons. Also, they suffer post-transcriptional modifications, such as splicing and 5′ capping \[[@B131-ijms-18-01514]\]. The importance of these molecules resides in their action as regulators of gene expression. LncRNAs may function by repressing the translation of nearby (*cis*) or faraway (*trans*) genes, by histone modifications or by interfering with the regulatory mechanisms of miRNAs \[[@B13-ijms-18-01514],[@B132-ijms-18-01514],[@B133-ijms-18-01514]\]. The use of lncRNAs as molecular biomarkers emerged with the characterization of the long noncoding RNA PCA3 (prostate cancer antigen 3) and the finding of its upregulated expression in prostate cancer patients \[[@B134-ijms-18-01514]\].

Like other non-coding RNAs, these lncRNA transcripts were related to a wide range of cancer types, including bladder cancer. Alterations in the expression level of these transcripts were proved to modulate an important number of cellular functions, starting with cell proliferation or differentiation, resistance to apoptosis, activation of drug resistance mechanisms or even activation of proangiogenic factors, that eventually contribute to increased invasion and metastatic capacity of tumor cells \[[@B135-ijms-18-01514]\]. Regarding their role in bladder cancer, these non-coding RNAs gained interest in recent years, when the number of studies increased considerably. [Table 2](#ijms-18-01514-t002){ref-type="table"} presents the studies published since 2010 that evaluated the expression of different lncRNAs and their putative activity as biomarkers in different types of bladder cancer.

The implication of lncRNAs in bladder cancer tumorigenesis is also reflected in the transcribed ultraconserved regions of the genome, which represent a new type of long noncoding RNAs. It was reported that these transcribed ultraconserved regions act by complementary binding to the sequence of a gene \[[@B136-ijms-18-01514]\].

LncRNAs interact with different mRNAs and/or other non-coding RNAs, thus modulating the expression of these transcripts and influencing pathways and processes that lead to the malignant transformation of normal cells into bladder cancer cells. The action of lncRNAs towards chromatin has the capacity to modulate the expression of genes localized near its genomic region (*cis*) or at considerable distance from it (*trans*) \[[@B131-ijms-18-01514]\]. Many studies investigated the association of different lncRNAs with mRNAs of genes which are pivotal in different pathways related to cancer. [Table 3](#ijms-18-01514-t003){ref-type="table"} lists the studies that evaluated these associations in bladder cancer cell lines. As it can be noted in [Table 3](#ijms-18-01514-t003){ref-type="table"}, the interactions between lncRNAs and mRNA/miRNA influence the EMT pathway. The HOTAIR/*ZEB1* interaction affects the EMT in bladder cancer cell lines, HOTAIR being known as a lncRNA associated with tumorigenesis, regulating invasion and cell migration \[[@B151-ijms-18-01514]\]. Likewise, MALAT-1*/E-cadherin* \[[@B159-ijms-18-01514]\] and UCA-1*/ZEB1/2* \[[@B184-ijms-18-01514]\] represent connections that contribute to invasion and metastasis, and were validated in bladder cancer cell lines in a TGF-β-dependent manner \[[@B159-ijms-18-01514]\], or through the hsa-miR-145/ZEB1/2/FSCN1 pathway \[[@B184-ijms-18-01514]\]. The Warburg effect is also depicted in the interactions of UCA-1/miR-143 that affects glycolysis via the mTOR-STAT3 pathway \[[@B185-ijms-18-01514]\]. The way that lncRNAs influence the malignant transformation---disturbing processes as survival, apoptosis, growth, invasion, and Warburg effect---is summarized in [Figure 2](#ijms-18-01514-f002){ref-type="fig"}.

2.3. Cell Free microRNAs {#sec2dot3-ijms-18-01514}
------------------------

There are many processes associated with carcinogenesis that are specific for the tumor stage, grade, aggressiveness, and even for its capacity to metastasize. Some of these abnormalities may also be reflected in specific patterns of miRNA expression in the malignant tissue \[[@B189-ijms-18-01514],[@B190-ijms-18-01514]\]. Conceivably, these modifications may be identified in biofluids, making these miRNAs suitable for their use as minimally invasive biomarkers for cancer detection \[[@B191-ijms-18-01514]\]. These circulating miRNAs can be identified in biofluids in association with ribonucleoprotein complexes, such as Argonaute proteins, or carried by particular extracellular vesicles, including exosomes or other microvesicles \[[@B192-ijms-18-01514],[@B193-ijms-18-01514]\]. There is evidence that indicates the contribution of miRNAs in tumor development, as their release from metastatic cells increases in the blood stream \[[@B194-ijms-18-01514]\]. In bladder cancer, there are various studies that use miRNA expression patterns as biomarkers with prognostic significance, but also for differentiating between the NMIBC and MIBC subtypes \[[@B195-ijms-18-01514],[@B196-ijms-18-01514],[@B197-ijms-18-01514],[@B198-ijms-18-01514],[@B199-ijms-18-01514]\]. Therefore, evaluating the expression of several miRNAs in serum samples, a functional panel of diagnosis biomarkers for MIBC was established, including the aberrantly expressed miR-422a-3, miR-486-3p, miR-103a-3p, and miR-27a-3p. Besides, these miRNAs represent valuable predictors of outcome \[[@B195-ijms-18-01514]\]. At the same time, circulating miRNA expression profiles can represent a signature for bladder cancer, as it was identified a 6-microRNA panel (miR-152, miR-148b-3p, miR-3187-3p, miR-15b-5p, miR-27a-3p and miR-30a-5p) that could be useful for the diagnosis of bladder cancer \[[@B196-ijms-18-01514]\]. In plasma samples, overexpression of miR-205 can represent a biomarker for the early detection of bladder cancer and appears to be associated with poor prognosis \[[@B197-ijms-18-01514]\]. Another study explored the use of urinary miRNAs in bladder cancer, revealing that downregulation of miR-125b in urine supernatant can discriminate between patients with bladder cancer and healthy volunteers \[[@B199-ijms-18-01514]\]. Fendler and colleagues (2016) published a comprehensive table that encompasses studies that assessed miRNAs as potential biomarkers in the blood and urine of patients with bladder cancer \[[@B200-ijms-18-01514]\].

2.4. Mitochondrial miRNAs (mitoMiRs) {#sec2dot4-ijms-18-01514}
------------------------------------

The mitochondrion is an organelle with crucial importance in several cellular processes, such as metabolic pathways, fatty acid oxidation, aging, apoptosis, and autophagy \[[@B201-ijms-18-01514],[@B202-ijms-18-01514]\]. Regarding mitochondrial function, it is regulated by proteins encoded in the mitochondrial and nuclear genome \[[@B203-ijms-18-01514]\]. Studies show that, in human cell lines, the mitochondrial transcriptome comprises also non-coding RNAs, including miRNA \[[@B204-ijms-18-01514]\]. Therefore, there were indications that the processing of pre-miRNA molecules may take place in the mitochondria, producing mature miRNAs able to target mitochondrial transcripts, or which are transported back to the cytosol, where they can modulate the expression of the nuclear transcripts. These miRNAs appear to be confined, and in association with the mitochondria \[[@B205-ijms-18-01514]\].

The presence of pre-miRNAs and mature miRNAs inside the mitochondria was reported by various studies \[[@B206-ijms-18-01514],[@B207-ijms-18-01514]\] and demonstrated through in situ hybridization for pre-mir-302a, pre-let-7b and mir-365 \[[@B208-ijms-18-01514]\]. One of the mechanisms that change a normal cell into a malignant one is highly connected to the Warburg effect \[[@B209-ijms-18-01514]\] and is driven by multiple factors, including the actions of various miRNAs \[[@B210-ijms-18-01514],[@B211-ijms-18-01514]\]. The Warburg effect intervenes under anaerobic conditions, and the final product of glycolysis, pyruvate, enters the Krebs cycle and is transformed into lactate \[[@B210-ijms-18-01514]\]. One example refers to the indirect action of miR-155 in a miR-143 dependent manner, resulting in the upregulation of hexokinase 2 (HK2)---an enzyme which influences the energy metabolism process demonstrated in breast cancer cells. Precisely, CCAAT/EBPβ is a transcriptional activator for miR-143, which acts as a negative regulator of the *HK2* gene. Upregulation of the *HK2* gene happens as a consequence of miR-155 repressing miR-143 \[[@B212-ijms-18-01514],[@B213-ijms-18-01514]\]. Furthermore, the tumor suppressant activity of miR-126 via regulation of mitochondrial function and metabolism in cancer cells was assessed in malignant mesothelioma \[[@B214-ijms-18-01514]\].

Up to date, there are no published studies regarding the role of mitochondrial miRNAs in bladder cancer. However, it was reported that lncRNA UCA1 derived from the mitochondrial transcriptome might contribute to the protection of the mitochondrial function, being actively involved in the reduction of reactive oxygen species (ROS) by targeting miR-16 in nasopharyngeal carcinoma tissues \[[@B215-ijms-18-01514]\].

2.5. The Role of Non-Coding RNAs in Warburg Effect {#sec2dot5-ijms-18-01514}
--------------------------------------------------

Metabolism is a key component of the tumor microenvironment. Therefore, the role of aerobic glycolysis---also called Warburg effect---has been extensively studied. In spite of the fact that the metabolic pathways altered in cancer are just beginning to be understood, there are already some non-coding RNAs that have been related to bladder cancer \[[@B216-ijms-18-01514]\]. The most relevant miRNAs that regulate this effect are those that target genes such as cMyc, HIF-1 and P53, active in tumor metabolism. There is the case of a lentiviral sponge for miRNA-21 that has the capacity to reduce glycolysis in bladder cancer T24 cells, via regulation of the PTEN/PI3K/AKT/mTOR axis. It was demonstrated that miR-195-5p inhibits the glucose uptake and proliferation of T24 bladder cancer cells, via modulation of glucose transporters \[[@B217-ijms-18-01514]\].

Presently, several therapeutic combinations are tested using miRNA mimics or inhibitors targeting the Warburg effect, for example the combination of synthetic miR-145 with siRNA for *PTBP1* \[[@B218-ijms-18-01514]\].

The biochemical aspects of the Warburg effect clearly demonstrate their relation to cell growth and proliferation. ANRIL is a well-known lncRNA in a wide range of malignant pathologies, including bladder cancer. Recently, these ncRNAs were demonstrated to regulate the expression of genes involved in glucose and fatty acid metabolism, such as *ADIPOR1*, *VAMP3* and *C11ORF10* \[[@B219-ijms-18-01514]\]. The lncRNA named urothelial cancer associated 1 (UCA1) has an oncogenic role considered to be related with disease progression, and appears to be a promising prognostic marker. UCA1 was associated with promoting glucose consumption and lactate production in bladder cancer cells via a mechanism regulated by HK2 mRNA expression through the mTOR--STAT3 pathway \[[@B185-ijms-18-01514]\]. It was reported that lincRNA-p21 has an important role in regulating Warburg effect via HIF-1α pathway \[[@B220-ijms-18-01514]\].

3. Challenges and Future Perspective {#sec3-ijms-18-01514}
====================================

The advance of medical technologies allowed the progress in oncological research, leading to a better understanding of the molecular aspects underlying the initiation and development of threatening malignancies. In this context, researchers found that specific untranslated parts of the genome, specifically miRNAs and lncRNAs, are able to influence, at transcriptomic and translational level, the expression of their target genes. This regulation mechanism based on complementary interactions is finely controlled in homeostatic states; however, the balance is lost in malignant scenarios where oncogenic miRNAs and lncRNAs are usually overexpressed, and the tumor suppressor ones are inhibited. This allowed researchers to investigate the extended role of non-coding RNAs in cancer development and progression, and their essential part in precision medicine applications. This review illustrates that both miRNAs and lncRNAs regulate the expression of their target genes, influencing pathways that control the metastatic process, migration, invasion, cell cycle arrest, and cell proliferation of bladder cancer cells. Besides, the presence and the action of particular cells within the tumor microenvironment complete the perturbations that cause tumor heterogeneity in bladder cancer patients. The data accumulating in this field can offer a perspective regarding the molecular profile of patients with bladder cancer in order to use these non-coding RNAs as therapeutic agents designed to target crucial genes dysregulated in bladder cancer, as applications in precision medicine. In this regard, ncRNA expression profiles from tissue, but also from body fluids, can become valuable diagnosis and prognosis markers, where the expression of the target sequences is markedly different between healthy controls and malignant groups. Moreover, specific sets of non-coding RNAs can be used to differentiate between cancer stages and even cancer subtypes. In terms of novel therapeutic alternatives, inhibition of oncogenic miRNAs, and more recently lncRNAs, or overexpression of tumor suppressor ones is also starting to make its way into the clinic. Due to the capacity of ncRNAs to target multiple genes and influence extended signaling networks, experimental modulation of these sequences is opening new alternatives for precision medicine, where patients can be treated according to their individual genetic profile. To conclude, this review gathers the studies that assessed the aberrant expression of miRNAs and lncRNAs, in order to offer a detailed perspective about the non-coding profile in bladder cancer, a profile with valuable meaning in the context of new diagnosis and prognosis tools, but also alternative therapeutic strategies.
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![Processes affected by different microRNAs (miRNAs) that were found to be dysregulated in patients with bladder cancer. Cancer cells are subjected to different molecular mechanisms in order to proliferate and invade secondary sites. The main hallmarks consist in survival and proliferation, development of new vascular networks and acquisition of invasive characteristics within epithelial to mesenchymal transition (EMT). All these processes are controlled by aberrantly expressed miRNAs, throughout the progression of tumor cells towards metastasis. In red are represented the upregulated microRNAs and in green those downregulated in bladder cancer; the arrow represents promotion of a process, and the T bar represents suppression of a process.](ijms-18-01514-g001){#ijms-18-01514-f001}

![The involvement of lncRNAs in different processes associated with the hallmarks of cancer in bladder malignancies. LncRNAs support the survival and growth of cancer cells (**A**) through interaction with specific target genes and modulation of cell metabolism (**B**). Once the tumor is formed, malignant cells are influenced by non-coding sequences in order to switch towards migratory mesenchymal cells (**C**) within EMT. Apoptosis is also influenced by lncRNAs that are able to target specific genes involved in programmed cell death (**D**) and support the progression of carcinogenesis.](ijms-18-01514-g002){#ijms-18-01514-f002}
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###### 

Studies reporting the validated target genes for miRNAs in bladder cancer cells.

  miRNA                 Expression   Target Genes                   Pathway                                    Reference
  --------------------- ------------ ------------------------------ ------------------------------------------ ---------------------------
  miR-9                 ↑            *CBX7*                                                                    \[[@B40-ijms-18-01514]\]
  miR-9                 ↑            *LASS2*                                                                   \[[@B41-ijms-18-01514]\]
  miR-19a               ↑            *PTEN*                         AKT/PKB signaling                          \[[@B42-ijms-18-01514]\]
  miR-21                ↑            *BCL-2*                        PI3K-AKT                                   \[[@B36-ijms-18-01514]\]
  miR-24-3p             ↑            *DEDD*                                                                    \[[@B43-ijms-18-01514]\]
  miR-92                ↑            *GSK3β*                        Wnt/c-myc/MMP7 signaling                   \[[@B44-ijms-18-01514]\]
  miR-92b               ↑            *DAB2IP*                       EMT                                        \[[@B32-ijms-18-01514]\]
  miR-96                ↑            *CDKN1A*                                                                  \[[@B45-ijms-18-01514]\]
  miR-129               ↑            *SOX4*                                                                    \[[@B25-ijms-18-01514]\]
  miR-130b              ↑            *PTEN*                         PI3K/AKT signaling                         \[[@B46-ijms-18-01514]\]
  miR-135a              ↑            *PHLPP2*, *FOXO1*              AKT signaling                              \[[@B47-ijms-18-01514]\]
  miR-137               ↑            *PAQR3*                                                                   \[[@B48-ijms-18-01514]\]
  miR-138-5p            ↑            *BIRC5*                                                                   \[[@B49-ijms-18-01514]\]
  miR-150               ↑            *PDCD4*                                                                   \[[@B50-ijms-18-01514]\]
  miR-155               ↑            *DMTF1*                                                                   \[[@B51-ijms-18-01514]\]
  miR-182-5p            ↑            *RECK*, *Smad4*                                                           \[[@B52-ijms-18-01514]\]
  miR-193a-3p           ↑            *LOXL4*, *SRSF2*               Oxidative Stress                           \[[@B53-ijms-18-01514]\]
  miR-200               ↑            *ERRFI-1*                      EGFR inhibitor resistance                  \[[@B54-ijms-18-01514]\]
  miR-222               ↑            *PPP2R2A*                      PPP2R2A/AKT/mTOR signaling                 \[[@B55-ijms-18-01514]\]
  miR-301a/b            ↑            *PTEN*                         PI3K/AKT signaling                         \[[@B46-ijms-18-01514]\]
  miR-495               ↑            *PTEN*                                                                    \[[@B56-ijms-18-01514]\]
  miR-1                 ↓            *LASP1*                                                                   \[[@B57-ijms-18-01514]\]
  miR-1                 ↓            *TAGLN2*                                                                  \[[@B58-ijms-18-01514]\]
  miR-1                 ↓            *SRSF9*                                                                   \[[@B59-ijms-18-01514]\]
  miR-1                 ↓            *PTMA*, *PNP*                                                             \[[@B60-ijms-18-01514]\]
  miR-1                 ↓            *UCA1*                                                                    \[[@B61-ijms-18-01514]\]
  miR-23b               ↓            *Zeb-1*                        EMT                                        \[[@B33-ijms-18-01514]\]
  miR-24                ↓            *CARMA3*                       EMT                                        \[[@B62-ijms-18-01514]\]
  miR-24-1              ↓            *FOXM1*                                                                   \[[@B63-ijms-18-01514]\]
  miR-26a               ↓            *HMGA1*                                                                   \[[@B64-ijms-18-01514]\]
  miR-26a-5p            ↓            *PLOD2*                                                                   \[[@B65-ijms-18-01514]\]
  miR-26b-5p            ↓            *PLOD2*                                                                   \[[@B65-ijms-18-01514]\]
  miR-27a               ↓            *SLC7A11*                      Glutathione biosynthesis                   \[[@B66-ijms-18-01514]\]
  miR-27a               ↓            *RUNX-1*                                                                  \[[@B67-ijms-18-01514]\]
  miR-29c               ↓            *BCL-2*, *MCL1*                                                           \[[@B68-ijms-18-01514]\]
  miR-29c               ↓            *CDK6*                         G1 phase arrest                            \[[@B69-ijms-18-01514]\]
  miR-31                ↓            *ITGA5*                        AKT and ERK                                \[[@B70-ijms-18-01514]\]
  miR-34a               ↓            *Cdk-6*, *SIRT-1*                                                         \[[@B71-ijms-18-01514]\]
  miR-34a               ↓            *CD44*                         EMT                                        \[[@B72-ijms-18-01514]\]
  miR-34a               ↓            *HNF4G*                                                                   \[[@B73-ijms-18-01514]\]
  miR-99a               ↓            *FGFR3*                                                                   \[[@B74-ijms-18-01514]\]
  miR-99a               ↓            *FGFR3*                                                                   \[[@B75-ijms-18-01514]\]
  miR-100               ↓            *FGFR3*                                                                   \[[@B74-ijms-18-01514]\]
  miR-100               ↓            *mTOR*                                                                    \[[@B76-ijms-18-01514]\]
  miR-101               ↓            *COX-2*                                                                   \[[@B77-ijms-18-01514]\]
  miR-101               ↓            *VEGF-C*                                                                  \[[@B78-ijms-18-01514]\]
  miR-101               ↓            *c-FOS*                                                                   \[[@B79-ijms-18-01514]\]
  miR-106a              ↓            *cyclin D1/CDK6*                                                          \[[@B80-ijms-18-01514]\]
  miR-122               ↓            *VEGFC*                        mTOR and AKT                               \[[@B81-ijms-18-01514]\]
  miR-124               ↓            *Cdk4*                                                                    \[[@B82-ijms-18-01514]\]
  miR-124               ↓            *UHRF1*                                                                   \[[@B83-ijms-18-01514]\]
  miR-124-3p            ↓            *ROCK1*                        EMT                                        \[[@B34-ijms-18-01514]\]
  miR-125b              ↓            *E2F3*                         E2F3--Cyclin A2 signaling                  \[[@B84-ijms-18-01514]\]
  miR-125b              ↓            *MMP13*                                                                   \[[@B85-ijms-18-01514]\]
  miR-125b              ↓            *SphK1*                        G1 phase arrest                            \[[@B86-ijms-18-01514]\]
  miR-126               ↓            *ADAM9*                                                                   \[[@B87-ijms-18-01514]\]
  miR-126               ↓            *PIK3R2*                       PI3K/AKT signaling                         \[[@B88-ijms-18-01514]\]
  miR-128               ↓            *VEGF-C*                                                                  \[[@B89-ijms-18-01514]\]
  miR-1280              ↓            *ROCK1*                                                                   \[[@B90-ijms-18-01514]\]
  miR-130b-3p           ↓            *PTEN*                         PI3K and integrin β1/FAK signaling         \[[@B91-ijms-18-01514]\]
  miR-133a              ↓            *LASP1*                                                                   \[[@B57-ijms-18-01514]\]
  miR-133a              ↓            *TAGLN2*                                                                  \[[@B58-ijms-18-01514]\]
  miR-133a              ↓            *PTMA*, *PNP*                                                             \[[@B60-ijms-18-01514]\]
  miR-133a/b            ↓            *EGFR*, *MMP-2*                                                           \[[@B92-ijms-18-01514]\]
  miR-133b              ↓            *Bcl-w*, *AKT1*                                                           \[[@B37-ijms-18-01514]\]
  miR-138               ↓            *ZEB2*                                                                    \[[@B93-ijms-18-01514]\]
  miR-139-3p/5p         ↓            *MMP11*                                                                   \[[@B94-ijms-18-01514]\]
  miR-143               ↓            *IGF-1R*                                                                  \[[@B95-ijms-18-01514]\]
  miR-143/145 cluster   ↓            *PAI-1*                                                                   \[[@B96-ijms-18-01514]\]
  miR-144               ↓            *EZH2*                         Wnt signaling/EZH2/Nkd1                    \[[@B97-ijms-18-01514]\]
  miR-144-5p            ↓            *CCNE1/2*, *CDC25A*                                                       \[[@B31-ijms-18-01514]\]
  miR-145               ↓            *FSCN1*                                                                   \[[@B98-ijms-18-01514]\]
  miR-145               ↓            *SOCS7*                        PI3K/AKT signaling                         \[[@B99-ijms-18-01514]\]
  miR-145               ↓            *PAK1*                                                                    \[[@B100-ijms-18-01514]\]
  miR-145               ↓            *IGF-IR*                                                                  \[[@B101-ijms-18-01514]\]
  miR-145-3p/5p         ↓            *UHRF1*                                                                   \[[@B102-ijms-18-01514]\]
  miR-146-3p            ↓            *PTTG1*                                                                   \[[@B103-ijms-18-01514]\]
  miR-148a-3p           ↓            *ERBB3*, *DNMT1, AKT2*                                                    \[[@B104-ijms-18-01514]\]
  miR-1826              ↓            *VEGFC*, *CTNNB1, MAP2K1*      MAPK-ERK signal transduction               \[[@B105-ijms-18-01514]\]
  miR-186               ↓            *NSBP1*                                                                   \[[@B106-ijms-18-01514]\]
  miR-193-3p            ↓            *HOXC9*                        DNA damage response and oxidative stress   \[[@B107-ijms-18-01514]\]
  miR-194               ↓            *RAP2B*                                                                   \[[@B108-ijms-18-01514]\]
  miR-195               ↓            *Cdk4*                         G1-phase arrest                            \[[@B109-ijms-18-01514]\]
  miR-195               ↓            *Cdc42*                        Cdc42/STAT3 signaling                      \[[@B110-ijms-18-01514]\]
  miR-195/497 cluster   ↓            *BIRC5*, *WNT7A*                                                          \[[@B21-ijms-18-01514]\]
  miR-199-3p/5p         ↓            *ITGA3*                                                                   \[[@B111-ijms-18-01514]\]
  miR-199a-3p/5p        ↓            *ITGA3*                                                                   \[[@B111-ijms-18-01514]\]
  miR-199a-5p           ↓            *MLK3*                         MLK3/IκB/NF-κB                             \[[@B112-ijms-18-01514]\]
  miR-199a-5p           ↓            *CCR7*                         EMT                                        \[[@B35-ijms-18-01514]\]
  miR-200c              ↓            *BMI-1*, *E2F3*                EMT                                        \[[@B113-ijms-18-01514]\]
  miR-203               ↓            *bcl-w*                                                                   \[[@B114-ijms-18-01514]\]
  miR-203               ↓            *AKT2*, *Src*                  PI3K/AKT signaling                         \[[@B115-ijms-18-01514]\]
  miR-205               ↓            *CCNJ*                                                                    \[[@B116-ijms-18-01514]\]
  miR-206               ↓            *YRDC*                                                                    \[[@B104-ijms-18-01514]\]
  miR-214               ↓            *PDRG1*                                                                   \[[@B117-ijms-18-01514]\]
  miR-218               ↓            *LASP1*                                                                   \[[@B57-ijms-18-01514]\]
  miR-218               ↓            *BMI-1*                        PI3K/AKT signaling                         \[[@B118-ijms-18-01514]\]
  miR-218               ↓            *Glut1*                                                                   \[[@B119-ijms-18-01514]\]
  miR-320c              ↓            *Cdk6*                         G1-phase arrest                            \[[@B120-ijms-18-01514]\]
  miR-320s              ↓            *ITGB3*                                                                   \[[@B121-ijms-18-01514]\]
  miR-335               ↓            *ROCK1*                                                                   \[[@B122-ijms-18-01514]\]
  miR-335               ↓            *MAPK1*                                                                   \[[@B38-ijms-18-01514]\]
  miR-409-3p            ↓            *c-Met*                                                                   \[[@B123-ijms-18-01514]\]
  miR-429               ↓            *E-cad*, *ZEB1/2, β-catenin*   EMT                                        \[[@B124-ijms-18-01514]\]
  miR-430               ↓            *CXCR3*                                                                   \[[@B125-ijms-18-01514]\]
  miR-433               ↓            *CREB*, *c-Met*                c-Met/AKT/GSK-3β/Snail signaling, EMT      \[[@B126-ijms-18-01514]\]
  miR-451               ↓            *c-Myc*                                                                   \[[@B127-ijms-18-01514]\]
  miR-485-5p            ↓            *HMGA2*                        EMT                                        \[[@B128-ijms-18-01514]\]
  miR-490-5p            ↓            *c-FOS*                        G1-phase arrest                            \[[@B129-ijms-18-01514]\]
  miR-490-5p            ↓            *c-FOS*                                                                   \[[@B130-ijms-18-01514]\]

AKT/PKB, Protein kinase B; PI3K-AKT, Phosphatidylinositol-4,5-bisphosphate 3-kinase-Protein kinase B; EMT, epithelial-mesenchymal transition; EGFR, Epidermal growth factor receptor; PPP2R2A, Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform; ↑, upregulated expression; ↓, downregulated expression.
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###### 

Studies assessing the expression of different long non-coding RNAs (lncRNAs) in bladder cancer patients.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  lncRNA                    Tumor Type                    Study                                                                                         Expression                          Reference
  ------------------------- ----------------------------- --------------------------------------------------------------------------------------------- ----------------------------------- ---------------------------
  AATBC                     Bladder cancer                90 patients\                                                                                  ↑ 54 cases\                         \[[@B137-ijms-18-01514]\]
                                                          90 adjacent normal tissue                                                                     ↓ 36 cases                          

  ANRIL                     Bladder cancer                51 patients\                                                                                  ↑                                   \[[@B138-ijms-18-01514]\]
                                                          51 adjacent non-tumor tissues                                                                                                     

  BANCR                     Bladder cancer                54 patients\                                                                                  ↓                                   \[[@B139-ijms-18-01514]\]
                                                          54matched adjacent normal tissues                                                                                                 

  GAS5                      Urothelial carcinoma          28 patients\                                                                                  ↓                                   \[[@B140-ijms-18-01514]\]
                                                          28 adjacent normal mucosa                                                                                                         

  GAS5                      Transitional cell carcinoma   82 patients\                                                                                  ↓                                   \[[@B141-ijms-18-01514]\]
                                                          37 normal bladder tissues                                                                                                         

  GHET-1                    Bladder cancer                80 patients\                                                                                  ↑                                   \[[@B142-ijms-18-01514]\]
                                                          80 adjacent normal tissues                                                                                                        

  H19                       Transitional cell carcinoma   39 patients                                                                                   ↑                                   \[[@B143-ijms-18-01514]\]

  H19                       Urothelial carcinoma          41 patients\                                                                                  ↑                                   \[[@B144-ijms-18-01514]\]
                                                          41 adjacent normal mucosa                                                                                                         

  H19                       Urothelial carcinoma          24 patients\                                                                                  ↑                                   \[[@B145-ijms-18-01514]\]
                                                          24 adjacent normal control tissues                                                                                                

  H19                       Bladder cancer                40 patients\                                                                                  ↑                                   \[[@B146-ijms-18-01514]\]
                                                          19 adjacent normal tissues                                                                                                        

  HIF1A-AS2                 Bladder cancer                44 patients\                                                                                  ↑                                   \[[@B147-ijms-18-01514]\]
                                                          44 matched normal peritumoral tissues                                                                                             

  HOTAIR                    Urothelial carcinoma          110 patients\                                                                                 ↑ 90 cases\                         \[[@B148-ijms-18-01514]\]
                                                          110 matched normal tissues                                                                    ↓ 20 cases                          

  HOTAIR                    Urothelial carcinoma          Set 1: 19 patients, 10 normal bladder tissues\                                                Set 1: ↑ 9 cases\                   \[[@B149-ijms-18-01514]\]
                                                          Set 2: 108 patients,\                                                                         Set 2: No significant differences   
                                                          7 normal bladder tissues                                                                                                          

  HOTAIR                    Transitional cell carcinoma   35 patients\                                                                                  ↑                                   \[[@B150-ijms-18-01514]\]
                                                          16 normal bladder transitional cell                                                                                               

  HOTAIR\                   Bladder cancer                10 patients\                                                                                  ↑\                                  \[[@B151-ijms-18-01514]\]
  MALAT-1                                                 10 distal normal tissue                                                                       ↑                                   

  HOTAIR                    NMIBC                         64 patients\                                                                                  ↑                                   \[[@B152-ijms-18-01514]\]
                                                          64 distant normal mucosa                                                                                                          

  LINC00312                 Bladder cancer                110 patients                                                                                  ↓                                   \[[@B153-ijms-18-01514]\]

  Linc-UBC1                 Bladder cancer                102 patients\                                                                                 ↑ 60 cases\                         \[[@B154-ijms-18-01514]\]
                                                          102 adjacent normal mucosa                                                                    ↓ 42 cases                          

  LOC572558                 Bladder cancer                24 patients\                                                                                  ↓                                   \[[@B155-ijms-18-01514]\]
                                                          24 matched normal bladder tissue                                                                                                  

  MALAT-1                   Bladder cancer                22 patients\                                                                                  ↑                                   \[[@B156-ijms-18-01514]\]
                                                          22 matched normal tissues                                                                                                         

  MALAT-1                   Urothelial carcinoma          36 patients\                                                                                  ↑                                   \[[@B157-ijms-18-01514]\]
                                                          36 matched histologically normal urothelium                                                                                       

  MALAT-1                   Urothelial carcinoma          27 patients\                                                                                  ↑                                   \[[@B158-ijms-18-01514]\]
                                                          27 adjacent histologically normal tissues                                                                                         

  MALAT-1                   Urothelial carcinoma          95 patients\                                                                                  ↑                                   \[[@B159-ijms-18-01514]\]
                                                          95 matched normal tissues                                                                                                         

  MDC1-AS                   Bladder cancer                32 patients\                                                                                  ↓                                   \[[@B160-ijms-18-01514]\]
                                                          32 adjacent normal tissue                                                                                                         

  MEG3                      Urothelial carcinoma          31 patients\                                                                                  ↓                                   \[[@B161-ijms-18-01514]\]
                                                          31 adjacent benign tissues                                                                                                        

  MIR31HG                   Bladder cancer                55 patients\                                                                                  ↓                                   \[[@B162-ijms-18-01514]\]
                                                          55 matched non-tumor bladder tissues                                                                                              

  MIR31HG                   Bladder cancer                55 patients\                                                                                  ↓                                   \[[@B162-ijms-18-01514]\]
                                                          55 adjacent normal tissue                                                                                                         

  n336928                   Bladder cancer                95 patients\                                                                                  ↑                                   \[[@B163-ijms-18-01514]\]
                                                          95 adjacent non-tumor tissues                                                                                                     

  ncRAN                     Transitional cell carcinoma   40 patients\                                                                                  ↑                                   \[[@B164-ijms-18-01514]\]
                                                          40 paired adjacent noncancerous tissues                                                                                           

  NEAT1                     Bladder cancer                65 patients\                                                                                  ↑ 48 cases                          \[[@B165-ijms-18-01514]\]
                                                          65 adjacent normal tissue                                                                                                         

  PCAT-1                    Urothelial carcinoma          36 patients\                                                                                  ↑                                   \[[@B166-ijms-18-01514]\]
                                                          36 matched normal tissues                                                                                                         

  PVT1                      Bladder cancer                32 patients\                                                                                  ↑ 20 cases                          \[[@B167-ijms-18-01514]\]
                                                          32 matched para-cancer tissues                                                                                                    

  SChLAP1                   Urothelial carcinoma          36 patients\                                                                                  ↑                                   \[[@B168-ijms-18-01514]\]
                                                          36 paired normal bladder tissue                                                                                                   

  SPRY4-IT1                 Urothelial carcinoma          68 patients\                                                                                  ↑                                   \[[@B169-ijms-18-01514]\]
                                                          68 adjacent non-tumor tissues                                                                                                     

  SPRY4-IT1                 Bladder cancer                60 patients\                                                                                  ↑                                   \[[@B170-ijms-18-01514]\]
                                                          60 matched normal adjacent tissue                                                                                                 

  TUG1                      Urothelial carcinoma          44 patients\                                                                                  ↑                                   \[[@B171-ijms-18-01514]\]
                                                          44 matched histologically normal urothelium                                                                                       

  TUG1                      Bladder cancer                36 patients\                                                                                  ↑                                   \[[@B172-ijms-18-01514]\]
                                                          36 adjacent normal tissue                                                                                                         

  TUG1                      Bladder cancer                54 patients                                                                                   ↑                                   \[[@B173-ijms-18-01514]\]

  TUG1                      Bladder cancer                47 patients\                                                                                  ↑                                   \[[@B174-ijms-18-01514]\]
                                                          47 adjacent non-tumor bladder tissues                                                                                             

  UCA1                      Urothelial carcinoma          34 patients (Cisplatin-based chemotherapy)                                                    ↑                                   \[[@B175-ijms-18-01514]\]

  UCA1                      Urothelial carcinoma          20 patients\                                                                                  ↑ 17 cases\                         \[[@B176-ijms-18-01514]\]
                                                          20 matched normal tissues                                                                     ↓ 3 cases                           

  UCA1                      Urothelial carcinoma          25 patients\                                                                                  ↑                                   \[[@B61-ijms-18-01514]\]
                                                          25 matched normal tissues                                                                                                         

  UCA1                      Transitional cell carcinoma   117 patients\                                                                                 ↑                                   \[[@B177-ijms-18-01514]\]
                                                          74 non bladder cancer patients                                                                                                    

  UCA1                      Bladder cancer                94 patients urine samples from patients with benign disease (56) or healthy volunteers (60)   ↑                                   \[[@B178-ijms-18-01514]\]

  UCA1                      Bladder cancer                184 patients (139 malignant disease+45 benign disease)\                                       ↑                                   \[[@B179-ijms-18-01514]\]
                                                          36 healthy volunteers                                                                                                             

  UCA1                      Bladder cancer                35 patients\                                                                                  ↑                                   \[[@B180-ijms-18-01514]\]
                                                          6 normal bladder tissues\                                                                                                         
                                                          10 adjacent normal tissues                                                                                                        

  UCA1a (CUDR)              Transitional cell carcinoma   8 patients\                                                                                   ↑                                   \[[@B181-ijms-18-01514]\]
                                                          8 adjacent normal mucosa                                                                                                          

  uc.8+\                    Bladder cancer                24 patients\                                                                                  ↑                                   \[[@B136-ijms-18-01514]\]
  (ultraconserved RNA 8+)                                 17 normal bladder epithelium                                                                                                      

  UNMIBC                    NMIBC                         75 patients\                                                                                  ↑ 45 cases                          \[[@B182-ijms-18-01514]\]
                                                          75 adjacent normal mucosa                                                                                                         

  ZEB2NAT                   Urothelial carcinoma          30 patients\                                                                                  ↑                                   \[[@B183-ijms-18-01514]\]
                                                          30 adjacent normal tissue                                                                                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AATBC, Apoptosis Associated Transcript In Bladder Cancer; ANRIL, Antisense Noncoding RNA in the INK4 Locus; BANCR, BRAF activated non-coding RNA; GAS5, Growth arrest-specific 5; GHET-1, gastric carcinoma high expressed transcript 1, HIF1A-AS2, hypoxia inducible factor 1 alpha-antisense RNA 2; HOTAIR, HOX transcript antisense RNA; LINC00312, long intergenic noncoding RNA; linc-UBC1, long intergenic RNA- Up-regulated in bladder cancer 1; MALAT-1, Metastasis Associated Lung Adenocarcinoma Transcript 1; MDC1-AS, mediator of DNA damage checkpoint protein 1antisense RNA; MEG3, maternally expressed 3; MIR31HG, host gene of miR-31; NEAT1, Nuclear Enriched Abundant Transcript 1; PCAT1, prostate cancer associated transcript 1; SChLAP1, SWI/SNF Complex Antagonist Associated With Prostate Cancer 1; SPRY4-IT1, SPRY4 intronic transcript 1; TUG1, taurine upregulated gene 1; UCA1, urothelial cancer associated 1; UNMIBC, up-regulated in nonmuscle invasive bladder cancer; ↑, upregulated expression; ↓, downregulated expression

ijms-18-01514-t003_Table 3

###### 

List of studies evaluating the expression of different lncRNAs and their putative target genes in bladder cancer.

  ----------------------------------------------------------------------------------------------------------------------------------------
  lncRNA      Association with Genes                                             Pathway                       Reference
  ----------- ------------------------------------------------------------------ ----------------------------- ---------------------------
  AATBC       ↑ *NRF2*                                                           JNK signaling                 \[[@B137-ijms-18-01514]\]

  AB074278    ↓ *EMP-1*                                                                                        \[[@B186-ijms-18-01514]\]

  ANRIL       ↓ *cleaved Caspase 9/3*, *cleaved PARP*, *Bax*, *Smac*, *cyt C*\   Intrinsic pathway             \[[@B138-ijms-18-01514]\]
              ↑ *Bcl-2*                                                                                        

  GAS5        ↓ *CDK6*                                                                                         \[[@B140-ijms-18-01514]\]

  GAS5        ↓ *CCL1*                                                                                         \[[@B187-ijms-18-01514]\]

  GAS5        ↓ *Bcl-2*                                                                                        \[[@B141-ijms-18-01514]\]

  GHET-1      ↓ *Snail*, *Slug*, *Twist*, *ZEB1*                                 EMT                           \[[@B142-ijms-18-01514]\]

  H19         *EHZ2*\                                                            Wnt/β-catenin                 \[[@B144-ijms-18-01514]\]
              ↓ *E-cadherin*                                                                                   

  H19         ↑ *ID2*                                                                                          \[[@B145-ijms-18-01514]\]

  HIF1A-AS2   ↑ *caspase 3*                                                                                    \[[@B147-ijms-18-01514]\]

  HOTAIR      ↓ *WIF-1*                                                          Wnt/β-catenin signaling       \[[@B148-ijms-18-01514]\]

  HOTAIR      ↓ *miR-205*                                                                                      \[[@B152-ijms-18-01514]\]

  HOTAIR      ↑ *SNAI1*, *ZEB1*, *TWIST1*, *MMP1*                                EMT                           \[[@B151-ijms-18-01514]\]

  LINC00312   ↓ *miR-197-3p*                                                                                   \[[@B153-ijms-18-01514]\]

  Linc-UBC1   *PRC complex*                                                                                    \[[@B154-ijms-18-01514]\]

  LOC572558   ↑ *AKT*, *MDM2*, *p53*                                             AKT-MDM2-p53 signaling axis   \[[@B155-ijms-18-01514]\]

  MALAT-1     ↓ *ZEB1*, *ZEB2*, *SLU*, *E-cadherin*                              Wnt/β-catenin                 \[[@B156-ijms-18-01514]\]

  MALAT-1     ↓ *E-cadherin*\                                                    EMT                           \[[@B159-ijms-18-01514]\]
              *SUZ12*                                                                                          

  SPRY4-IT1   ↓ *miR-101-3p*\                                                    EMT\                          \[[@B170-ijms-18-01514]\]
              ↑ *EZH2*                                                           EZH2 pathway                  

  SPRY4-IT1   ↑ *miR-101-3p*\                                                                                  \[[@B170-ijms-18-01514]\]
              ↓ *EZH2*                                                                                         

  TUG1        ↑ *ZEB2*\                                                          Wnt/β-catenin pathway         \[[@B172-ijms-18-01514]\]
              ↓ *miR-142*                                                                                      

  TUG1        ↓ *miR-145*                                                        EMT                           \[[@B173-ijms-18-01514]\]

  UCA-1       ↑ *HK2*\                                                           Glycolysis\                   \[[@B185-ijms-18-01514]\]
              ↓ *miR-143*                                                        mTOR--STAT3 pathway           

  UCA-1       ↑ *CREB*                                                           PI3-K/AKT                     \[[@B188-ijms-18-01514]\]

  UCA-1       ↑ *Wnt6*                                                           Wnt signaling                 \[[@B175-ijms-18-01514]\]

  UCA-1       ↓ *BRG1*                                                                                         \[[@B176-ijms-18-01514]\]

  UCA-1       ↑ *GLS2*                                                           Cell redox state\             \[[@B180-ijms-18-01514]\]
                                                                                 Glutaminolysis                

  UCA-1       ↑ *ZEB1/2*\                                                        EMT\                          \[[@B184-ijms-18-01514]\]
              ↓ *miR-145*                                                        miR-145--ZEB1/2--FSCN1        

  UNMIBC      *EZH2*, *SUZ12*                                                                                  \[[@B182-ijms-18-01514]\]

  ZEB2NAT     ↑ *TGF-β1*, *ZEB2*                                                 EMT                           \[[@B183-ijms-18-01514]\]
  ----------------------------------------------------------------------------------------------------------------------------------------
